Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 3, 2013, Pages 258-260

  Lim, Zita Dubauskas ^a   Mahajan, Anita ^a   Weinberg, Jeffrey ^a   Tannir, Nizar M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

brain metastases; renal cell carcinoma; sunitinib

Indexed keywords

DEXAMETHASONE; EVEROLIMUS; PAZOPANIB; SORAFENIB; SUNITINIB;

ADULT; AGED; ARTICLE; BRAIN DAMAGE; BRAIN EDEMA; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; HUMAN; KIDNEY CARCINOMA; LOCAL THERAPY; MALE; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; OUTCOME ASSESSMENT; PERILESIONAL EDEMA; STEREOTACTIC RADIOSURGERY; SYSTEMIC DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; FOLLOW-UP STUDIES; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PYRROLES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84878859505     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182467b9a     Document Type: Article

References (11)

1. Motzer RJ, Hutson TE, Tomc-zak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
2. Motzer RJ, Hutson TE, Tomc-zak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584-3590.
3. Seaman E. High incidence of asymptomatic brain lesions in metastatic renal cell carcinoma. J Neurooncol. 1995;23:253-256.
4. Medioni J, Cojocarsu O, Belaceres JL, et al. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol. 2007;18:1282-1283.
5. Koutros AK, Krikelis D, Alexandrou N, et al. Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res. 2007;27: 4255-4258.
6. Haznedar JO, Patyna S, Bella C. Single-and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in nonclinical species. Cancer Chemother Pharmacol. 2009;64:691-706.
7. Hariharan S, S-zczylik C, Porta C, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases: data from expanded access trial. J Clin Oncol. 2008;26(15s). May 20 suppl; abstract 5094.
8. Gore M, Hariharan S, Porta C, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer. 2011; 117:501-509.
9. Helgason HH, Mallo HA, Dorrkgendijk H, et al. Brain metastases in patients with renal cell carcinoma receiving new targeted therapy. J Clin Oncol. 2008;26:152-154.
10. Katayama T, Shiizu J, Suda K, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol. 2009;11:1415-1419.
11. Altavilla G, Arrigo C, Santarpia MC, et al. Erlotinib therapy in a patient with non-small cell lung cancer and brain metastases. J Neurooncol. 2008;90:31-33.